ALKEM LABORATORIES
|
ALKEM LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 192.54 | 181.14 | 150.21 | 82.32 | 137.65 |
| CEPS(Rs) | 228.79 | 215.24 | 176.56 | 110.18 | 165.98 |
| DPS(Rs) | 53.00 | 45.00 | 40.00 | 50.00 | 34.00 |
| Book NAV/Share(Rs) | 1,153.04 | 999.47 | 860.94 | 756.56 | 722.48 |
| Tax Rate(%) | 18.03 | 12.31 | 10.46 | 22.84 | 8.89 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.27 | 13.01 | 11.58 | 8.97 | 13.44 |
| EBIT Margin(%) | 13.43 | 13.72 | 11.02 | 7.87 | 12.42 |
| Pre Tax Margin(%) | 12.72 | 13.09 | 10.44 | 7.27 | 12.07 |
| PAT Margin (%) | 10.43 | 11.48 | 9.35 | 5.61 | 11.00 |
| Cash Profit Margin (%) | 12.12 | 13.33 | 10.89 | 7.34 | 12.99 |
| Performance Ratios | |||||
| ROA(%) | 13.44 | 14.77 | 13.66 | 7.99 | 14.50 |
| ROE(%) | 18.29 | 19.93 | 18.74 | 11.39 | 20.99 |
| ROCE(%) | 21.28 | 21.56 | 19.52 | 13.09 | 18.69 |
| Asset Turnover(x) | 1.29 | 1.29 | 1.46 | 1.42 | 1.32 |
| Sales/Fixed Asset(x) | 4.18 | 4.17 | 4.51 | 4.36 | 3.86 |
| Working Capital/Sales(x) | 3.04 | 2.82 | 3.02 | 3.66 | 4.21 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.24 | 0.24 | 0.22 | 0.23 | 0.26 |
| Receivable days | 44.04 | 44.62 | 41.28 | 40.86 | 41.72 |
| Inventory Days | 50.59 | 52.79 | 49.60 | 57.10 | 63.54 |
| Payable days | 167.84 | 163.20 | 122.87 | 97.40 | 114.79 |
| Valuation Parameters | |||||
| PER(x) | 27.54 | 26.94 | 32.89 | 41.27 | 26.28 |
| PCE(x) | 23.18 | 22.67 | 27.98 | 30.84 | 21.79 |
| Price/Book(x) | 4.60 | 4.88 | 5.74 | 4.49 | 5.01 |
| Yield(%) | 1.00 | 0.92 | 0.81 | 1.47 | 0.94 |
| EV/Net Sales(x) | 4.30 | 4.46 | 4.63 | 3.39 | 4.07 |
| EV/Core EBITDA(x) | 17.64 | 19.24 | 22.96 | 21.53 | 19.52 |
| EV/EBIT(x) | 20.88 | 21.84 | 27.48 | 27.84 | 22.80 |
| EV/CE(x) | 4.10 | 4.43 | 5.09 | 3.80 | 3.39 |
| M Cap / Sales | 4.31 | 4.50 | 4.66 | 3.50 | 4.07 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.48 | 2.34 | 9.21 | 9.08 | 19.96 |
| Core EBITDA Growth(%) | 19.38 | 17.59 | 40.03 | -17.60 | 1.84 |
| EBIT Growth(%) | 14.46 | 24.03 | 51.23 | -25.55 | -0.23 |
| PAT Growth(%) | 6.19 | 22.33 | 79.92 | -40.08 | 3.87 |
| EPS Growth(%) | 6.30 | 20.59 | 82.47 | -40.19 | 3.82 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | 0.09 | 0.12 | 0.14 | 0.30 |
| Current Ratio(x) | 2.55 | 2.73 | 2.61 | 2.32 | 1.76 |
| Quick Ratio(x) | 1.86 | 1.99 | 1.94 | 1.62 | 1.13 |
| Interest Cover(x) | 18.86 | 21.76 | 19.00 | 13.15 | 36.22 |
| Total Debt/Mcap(x) | 0.03 | 0.02 | 0.02 | 0.03 | 0.06 |
Compare Financial Ratios of peers of ALKEM LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALKEM LABORATORIES | ₹64,344.8 Cr | -2.4% | -3.1% | 13.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,675.0 Cr | -3% | -2.6% | 21.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹225,516.0 Cr | -0.5% | 17% | 43.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,190.0 Cr | 0.6% | 2.7% | 35.5% | Stock Analytics | |
| CIPLA | ₹115,523.0 Cr | -2.2% | 0.8% | -2.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,493.4 Cr | -1.1% | -1.6% | -0.8% | Stock Analytics | |
ALKEM LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALKEM LABORATORIES | -2.4% |
-3.1% |
13.3% |
| SENSEX | -1% |
0.7% |
-3.6% |
You may also like the below Video Courses
